[Other] Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure |
|
This post will be closed automatically in 2026-08-15 23:31
Reward20points
|
20
Inflammatory Bowel Disease
50
[Full book]▽Full BOOK▼Memory Art in the Contemporary World: Confronting Violence in the Global South
700
[Full book]Stratigraphy and paleontology of the Paleozoic of the Arctic
20
International Journal of Case Reports in Surgery
500
[Full book]Collins Cambridge Lower Secondary Science Teacher's Guide 7 2nd Edition
